| Excerpt | Reference |
|---|
| "While hair loss is usually of more psychologic than physiologic significance, accurate diagnosis can be of great importance." | ( Ackerman, AB; Stengel, F, 1978) |
| "The development of androgenetic alopecia is thought to be caused by increased androgen action on hair follicles with menopause." | ( Georgala, S; Gourgiotou, K; Kassouli, S; Stratigos, JD, 1992) |
| "Male pattern baldness is assumed to result from a combination of normal serum concentrations of androgen and an appropriate genetic background." | ( Conte, ET; Leavitt, ML; Nafz, MA; Schroeter, AL; Young, JW, 1991) |
| "Alopecia (hair loss) is among the most distressing side effects of cancer chemotherapy." | ( Hussein, AM; Jimenez, JJ; McCall, CA; Yunis, AA, 1990) |
| "Alopecia (hair loss) is often singled out as the most distressing side-effect of cancer chemotherapy treatment." | ( Tierney, AJ, 1987) |
| "Hair loss is a common problem likely to be encountered by a clinical practitioner." | ( Phillips, JH; Smith, SL; Storer, JS, 1986) |
| "The hair loss is obviously a consequence of the ichthyosiform erythroderma, and therefore we propose for this type of pseudopelade the term alopecia ichthyotica." | ( Happle, R; Traupe, H, 1983) |
| "When baldness is mild to extreme in the vertex or anterior vertex, scalp reduction is usually indicated." | ( Cates, JA; Dean, AJ; Stough, DB, 1982) |
| "Androgenetic alopecia is an androgen dependent disorder occurring in genetically susceptible individuals." | ( Callan, AW; Montalto, J, 1995) |
| "Hair loss is a common problem that may affect both males and females in all age groups." | ( Nielson, TA; Reichel, M, 1995) |
| "Temporary hair loss is well accepted as a possible result of psoriatic plaques." | ( Bonsmann, G; Kretzschmar, L; Luger, TA; Metze, D; Schwarz, T, 1995) |
| "Male pattern baldness is a common affliction affecting up to half the adult male population." | ( Duplechain, G; White, JA, 1994) |
| "Androgenetic alopecia is the most common cause of hair loss in men and women." | ( Jacobs, JP; Szpunar, CA; Warner, ML, 1993) |
| "Hair loss is common in patients with HIV-1 infection, and in black patients this loss may be associated with straightening." | ( Angritt, P; DeRusso, D; Skelton, HG; Smith, KJ; Sperling, L; Wagner, KF; Yeager, J, 1996) |
| "Hair loss is a side effect of many chemotherapeutic agents, and patients have even refused possibly palliative or lifesaving drugs because they could not accept temporary or prolonged baldness." | ( Bandstra, BA; Compton, LD; Duvic, M; Farmer, KL; Hortobagyi, GN; Hymes, SR; Lemak, NA; Trancik, RJ; Valero, V, 1996) |
| "Hair loss is a potentially distressing side-effect of several cytotoxic drugs." | ( Dougherty, L, 1996) |
| "Male pattern baldness is a common, androgen-dependent skin problem in adult men which is not well understood, although androgens are believed to act on the hair follicle via the mesenchyme-derived dermal papilla situated in the middle of the hair follicle bulb." | ( Hamada, K; Hibberts, NA; Randall, VA, 1996) |
| "Pseudopelade is a rare idiopathic progressive alopecia that has no initial inflammatory phase." | ( Sahl, WJ, 1996) |
| "Pseudopelade is an autosomal dominant disorder of the scalp marked by atrophic loss of hair follicles." | ( Sahl, WJ, 1996) |
| "The pathogenesis of androgenic alopecia is not fully understood." | ( Cauwenbergh, G; De Doncker, P; Piérard, GE; Piérard-Franchimont, C, 1998) |
| "Common baldness or androgenetic alopecia is a normal physiological process of hair loss in genetically predisposed individuals." | ( Sinclair, RD; Tran, D, 1999) |
| "Androgenetic alopecia is the most common form of hair loss in men and women." | ( Happle, R; Hoffmann, R, 1999) |
| "Data suggest that androgenetic alopecia is a process dependent on dihydrotestosterone (DHT) and type 2 5alpha-reductase." | ( Carrington, P; Cole, GW; Cotterill, PC; Dallob, A; Drake, L; Epstein, ES; Fiedler, V; Geissler, L; Gencheff, C; Griffin, EI; Hordinsky, M; Jacobson, C; Kraus, SJ; Lowe, N; Pariser, DM; Stieglitz, S; Swinehart, J; Tanaka, W; Thiboutot, DM; Unger, WP; Vandormael, K; Waldstreicher, J; Weiss, D; Whiting, D, 1999) |
| "Androgenetic alopecia is a common condition of adult men." | ( Bergfeld, W; DeVillez, R; Drake, L; Fiedler, V; Funicella, T; Gencheff, C; Hordinsky, M; Imperato-McGinley, J; Katz, I; Lowe, N; Lucky, A; Millikan, L; Muller, S; Olsen, E; Price, VH; Rietschel, R; Roberts, JL; Savin, R; Shupack, J; Stough, D; Swinehart, J; Weiss, D; Whiting, D; Whitmore, E, 1999) |
| "Androgenetic alopecia is a common dermatological condition, with potentially adverse psychosocial sequelae." | ( Cash, TF, 1999) |
| "Pseudopelade is a rare self-limited hair disorder, resulting in cicatricial alopecia." | ( Madani, S; Shapiro, J; Trotter, MJ, 2000) |
| "Hair loss is also related to hypothyroidism, which can be induced by lithium and other agents." | ( Khan, T; Lippmann, S; Mercke, Y; Sheng, H, 2000) |
| "Post-partum hair loss is possibly due to a reduction in the levels of oestradiol and thyroxine postnatally." | ( Pringle, T, 2000) |
| "Androgenetic alopecia is caused by the heightened sensitivity of scalp follicles to dihydro- testosterone whereas alopecia areata is induced by an autoimmune reaction." | ( Meidan, VM; Touitou, E, 2001) |
| "Female pattern hair loss is common but estimates of its prevalence have varied widely." | ( Birch, MP; Messenger, AG; Messenger, JF, 2001) |
| "Androgenetic alopecia is due to androgen-induced, non-synchronized, progressive shortening of the hair growth cycle and gradually leads to thinning of the central scalp area." | ( Trüeb, RM, 2002) |
| "Female pattern hair loss is a common condition characterized by a diffuse reduction in hair density over the crown and frontal scalp with retention of the frontal hairline." | ( Birch, MP; Lalla, SC; Messenger, AG, 2002) |
| "Androgenetic alopecia is the most common type of hair loss in men and women." | ( Hanneken, S; Kruse, R; Nöthen, MM; Ritzmann, S, 2003) |
| "Although androgenic alopecia is recognised to be a symptom of polycystic ovary syndrome (PCOS), it is not known whether polycystic ovaries (PCO) and associated endocrine abnormalities are present in patients who present with alopecia as a primary complaint." | ( Cela, E; Franks, S; Kingsley, P; Kousta, E; Lyons, G; McCarthy, MI; Robertson, C; Rush, K; White, DM; Wilson, H, 2003) |
| "Androgenic alopecia is a condition of concern for many patients." | ( Hernandez, BA, 2004) |
| "Hair loss is a common complaint in the outpatient setting." | ( Bandaranayake, I; Mirmirani, P, 2004) |
| "Hair loss is complex and can be classified in many ways." | ( Parsley, WM, 2004) |
| "Male pattern baldness is the result of premature entry into catagen due to androgens." | ( Hibino, T; Nishiyama, T, 2004) |
| "Medication-induced hair loss is an occasional adverse effect of many drugs used for neuropsychological diseases." | ( Ishii, A; Kohno, Y; Shoji, S, 2004) |
| "Localized scalp hair loss is associated with many processes, including alopecia areata, trichotillomania, tinea capitis, and early lupus erythematosus." | ( Mansouri, P; Mortazavi, M, 2004) |
| "Acne and androgenetic alopecia are linked to androgen effects and therefore should improve following topical application of antiandrogens." | ( Blume-Peytavi, U; Haberland, A; Jores, K; Korting, HC; Mehnert, W; Münster, U; Nakamura, C; Rummel, S; Schäfer-Korting, M; Schaller, M; Zouboulis, ChC, 2005) |
| "Hair loss is a distressing condition for an increasing number of men and women." | ( Chang, SY; Hwang, SL; Kim, CD; Lee, IH; Lee, MH; Park, SJ; Rang, MJ; Rho, SS, 2005) |
| "Female pattern hair loss is the commonest cause of hair loss in women and prevalence increases with advancing age." | ( Dinh, QQ; Sinclair, R, 2007) |
| "In both sexes the androgenetic alopecia is known to be mediated by the conversion of circulating androgens into dihydrotestosterone within the hair follicle." | ( Riedel, A; Riedel-Baima, B, 2008) |
| "Alopecia (hair loss) is experienced by thousands of cancer patients every year." | ( Chen, Q; Connelly, EA; Elgart, GW; Goldenberg, C; Jimenez, JJ; Mauro, LM; Mejia, J; Munson, JW; Roberts, SM; Voellmy, R; Zou, J, 2008) |
| "Hair loss is a common, bothersome problem among women." | ( Ever-Hadani, P; Gur, I; Kiderman, A, 2009) |
| "Female pattern hair loss is devastating to many of the 21 million U." | ( Leavitt, M, 2008) |
| "While this form of hair loss is widely recognized, and may even be on the rise, the causes of central centrifugal cicatricial alopecia are a constant source of debate and remain to be elucidated." | ( Gathers, RC; Lim, HW, 2009) |
| "Androgenic alopecia is known to be androgen-dependent." | ( Kavand, S; Meshkat-Razavi, G; Nabaie, L; Robati, RM; Sarrafi-Rad, N; Shahgholi, L, 2009) |
| "Hair loss is a very common complaint and dermatologists should be able to make the correct diagnosis of different types of alopecia and choose the best therapeutic strategy according to patients' and doctors' expectations." | ( Duque-Estrada, B; Tosti, A, 2009) |
| "Androgenic alopecia is the commonest type of baldness." | ( Soni, VK, 2009) |
| "Androgenetic alopecia is a common cosmetic hair disorder, resulting from interplay of genetic, endocrine, and aging factors leading to a patterned follicular miniaturization." | ( Abdel-Wahab, H; Attia, S; El-Domyati, M; Saleh, F, 2009) |
| "Androgenetic alopecia is recognized as a risk factor for cardiovascular diseases, glucose metabolism disorders, and benign prostate hyperplasia and/or carcinoma." | ( Duskova, M; Hill, M; Starka, L, 2010) |
| "Hair loss is an unwelcome event at any age, but it can be particularly distressing for adolescents and their families." | ( Cantatore-Francis, J; Gonzalez, ME; Orlow, SJ, 2010) |
| "Androgenetic alopecia is a progressive condition and although the current available treatments are effective in arresting the progression of the disease, they allow only partial regrowth of hair at its best." | ( Rathnayake, D; Sinclair, R, 2010) |
| "Patterned hair loss is progressive and when untreated leads to baldness." | ( Rathnayake, D; Sinclair, R, 2010) |
| "Traumatic hair loss is a scalp injury that can cause secondary scarring alopecia." | ( Ntuen, E; Stein, SL, 2010) |
| "Androgenetic alopecia is the most common form of alopecia in men." | ( Catalano, HN; Guyatt, G; Manzotti, M; Mella, JM; Perret, MC, 2010) |
| "Female pattern hair loss is a common but difficult to manage condition." | ( Sinclair, R; Yazdabadi, A, 2011) |
| "Female-pattern androgenetic alopecia is a very common disorder that has been associated with extreme psychological morbidity." | ( Emer, JJ; Markowitz, O; Stevenson, ML, 2011) |
| "Adolescent androgenic alopecia is pattern hair loss occurring in boys and girls younger than 18 years, whereas early-onset androgenic alopecia refers to pattern hair loss before 35 years of age." | ( McDonough, PH; Schwartz, RA, 2011) |
| "Female pattern hair loss is a common problem affecting a large number of women worldwide but beset by a paucity of research." | ( Mirmirani, P, 2011) |
| "Hair loss is a common problem for both men and women and may impact negatively on self-esteem." | ( Donovan, JC; Hordinsky, MK; Pierre-Louis, M; Shapiro, P; Shapiro, RL; Zupan, M, 2012) |
| "Scalp hair loss is often encountered in clinical practice in Japan after successful surgery for acromegaly." | ( Fukuhara, N; Nishioka, H; Takeshita, A; Takeuchi, Y; Yamada, S; Yamaguchi-Okada, M, 2013) |
| "Androgenetic alopecia is a common cause of hair loss in both men and women." | ( Banka, N; Bunagan, MJ; Shapiro, J, 2013) |
| "Role of iron in hair loss is not clear yet." | ( Cho, S; Kim, JH; Lee, JH; Na, SY; Park, SY, 2013) |
| "Some degree of hair loss is accepted as a normal part of the aging process, in line with the observation that more than 50% of men will develop androgenetic alopecia by the age of 50 years." | ( Basra, MK; Bhatti, HA; Patel, GK, 2013) |
| "Because androgenetic alopecia is progressive in nature, stabilization of the process using medical therapy is an important adjunct to any surgical hair-restoration plan." | ( Nusbaum, AG; Nusbaum, BP; Rose, PT, 2013) |
| "Female hair loss is a devastating issue for women that has only relatively recently been publicly acknowledged as a significant problem." | ( Unger, RH, 2013) |
| "Hair loss is commonly seen in autoimmune diseases." | ( Cozzani, E; Parodi, A, 2014) |
| "Drug-induced hair loss is an adverse reaction that has been identified during different hair growth phases." | ( Gil-Gómez, I; Lorente-Fernández, L; Monte-Boquet, E; Poveda-Andrés, JL; Ruiz-Ramos, J; Salavert-Lleti, M, 2014) |
| "Hair loss is most prominent after 6 weeks of chemotherapy." | ( Bangemann, N; Blume-Peytavi, U; Garcia Bartels, N; Hillmann, K; Kanti, V; Kleine-Tebbe, A; Lindner, J; Nuwayhid, R; Stroux, A, 2014) |
| "Male pattern androgenetic alopecia is characterized by progressive hair loss from the scalp." | ( Ataseven, A; Dokur, N; Gorur, A; Gumusalan, Y; Inaloz, S; Kurutas, E; Ozturk, P; Tamer, L, 2014) |
| "Hair loss is a common problem in captive macaque colonies." | ( Coleman, K; Hamel, AF; Lutz, CK; Menard, M; Meyer, JS; Novak, MA; Rosenberg, K; Ryan, A; Worlein, J, 2014) |
| "Hair loss is a frequent condition after sleeve gastrectomy." | ( Arroyo, A; Calero, A; Calpena, R; Diez, M; Llavero, C; Oller, I; Ruiz-Tovar, J; Zubiaga, L, 2014) |
| "Androgenetic alopecia is a common condition, with severe attendant psychosocial implications, and for which it is difficult to obtain a satisfactory degree of clinical improvement." | ( Abeni, D; Greco, J; Raskovic, D; Schiavone, G, 2014) |
| "Hair loss is a common cause of morbidity for many women." | ( Bechtel, MA; Harfmann, KL, 2015) |
| "Hair loss is common among patients with IBD." | ( Abraham, B; Hou, J; Sellin, J; Shah, R, 2015) |
| "Hair loss is also a serious event that could be a critical reason for patients to decline thiopurine treatment." | ( Endo, K; Kakuta, Y; Kimura, T; Kinouchi, Y; Kuroha, M; Naito, T; Negoro, K; Onodera, M; Shiga, H; Shimosegawa, T, 2016) |
| "Androgenetic alopecia is the progressive miniaturization of the scalp's terminal follicles in aging men." | ( Keaney, T, 2015) |
| "Male baldness is the most common diagnosis in men that present with hair loss." | ( Torres, F, 2015) |
| "Hair loss is not uncommon in the pediatric group, but its patterns in this group are different from those seen in adults." | ( Alves, R; Grimalt, R, 2015) |
| "Hair loss is related to follicular density, programmed regrowth and hair productivity." | ( Rushton, DH; Van Neste, DJ, 2016) |
| "Androgenetic alopecia is an androgen-induced pattern of progressive hair loss, which occurs in genetically predisposed people." | ( Brotherton, B; Irisawa, R; Ito, H; Kawashima, M; Manyak, M; Tsuboi, R; Tsunemi, Y; Yoshiie, H, 2016) |
| "Hair loss is common in macaque colonies." | ( Coleman, K; El-Mallah, SN; Lutz, CK; Menard, MT; Meyer, JS; Novak, MA; Rosenberg, K; Worlein, J, 2017) |
| "Transient hair loss is not a reported side effect of dimethyl-fumarate therapy but by excluding any known cause we attributed it to the beginning of the new therapy." | ( De Fino, C; Losavio, FA; Lucchini, M; Mirabella, M; Nociti, V, 2016) |
| "Hair loss is caused by a variety of hair growth disorders, each with its own pathogenetic mechanism." | ( Blume-Peytavi, U; Fischer, TW; Wolff, H, 2016) |
| "Hair loss is a symptom, not a diagnosis." | ( Blume-Peytavi, U; Fischer, TW; Wolff, H, 2016) |
| "Male pattern hair loss is widespread around the world." | ( Firooz, A; Halavati, N; Hasanzadeh, H; Nasrollahi, SA; Saberi, M, 2016) |
| "Hair loss is one of the most noticeable esthetic problems of the mankind." | ( Bagheri, H; Govsa, F; Ozer, MA; Pinar, Y; Sirinturk, S, 2017) |
| "Androgenetic alopecia is a common condition characterized by thinning of scalp hair." | ( Adil, M; Arif, T; Dorjay, K; Sami, M, 2017) |
| "Pattern hair loss is the most common form of hair loss in both women and men." | ( Betz, RC; Messenger, AG; Redler, S, 2017) |
| "Androgenetic alopecia is the most common form of hair loss." | ( Aliper, A; Consolo, M; Cooper, KD; McCormick, TS; Mirmirani, P; Ozerov, IV; Pappas, A; Schastnaya, J; Stamatas, GN; Wu, J; Zhavoronkov, A, 2017) |
| "Androgenetic alopecia is an extremely common dermatological disorder affecting both men and women." | ( Cruz, N; Dias, IS; Rebelo, A; Reis, CP; Rijo, P; Roberto, A; Roque, LV, 2017) |
| " INTRODUCTION: Hair loss is a common complaint seen in dermatology clinics." | ( DiMarco, G; McMichael, A, 2017) |
| "Androgenetic alopecia is a condition with a high prevalence worldwide and affects both males and females." | ( Anandan, S; Chitallia, J; Dhurat, R; Jayaraaman, AM; Klenk, A; Madhukara, J; May, TW; Vaidya, P, 2017) |
| "Androgenetic alopecia is the most common hair loss disorder, affecting both men and women." | ( Blume-Peytavi, U; Blumeyer, A; Del Marmol, V; Dobos, G; Finner, A; Kanti, V; Messenger, A; Nast, A; Piraccini, BM; Reygagne, P; Tosti, A; Trakatelli, M, 2018) |
| "Androgenetic alopecia is associated with a high psychological burden and often results in substantially reduced quality of life, poor body image and low self-esteem, particularly in women." | ( Bussoletti, C; Celleno, L; Tolaini, MV, 2020) |
| "Because hair loss is multifactorial, differenced and new approaches are required." | ( Marzani, B; Pinto, D; Rinaldi, F; Sorbellini, E, 2018) |
| "Hair loss is characterized by a shortened hair anagen phase and hair follicles (HF) miniaturization." | ( Jing, J; Lu, Z; Wang, H; Wu, X; Yu, L; Zhou, L, 2018) |
| "Hair loss is a common aesthetic disorder that can be triggered by genetic, inflammatory, hormonal, and environmental factors acting on hair follicles and their life cycle." | ( Brotzu, G; Campisi, M; Consolaro, F; Fadda, AM; Manca, ML; Manca, T; Marongiu, F, 2019) |
| "When hair loss is diffuse and severe, there were associations with haematologic (P = 0." | ( Chanprapaph, K; Suchonwanit, P; Thadanipon, K; Udompanich, S, 2019) |
| "The treatment of hair loss is a challenge for all dermatologists." | ( Santos, LDN; Shapiro, J, 2019) |
| "Cranial hair loss is one of the characteristics of age." | ( Cao, DX; Chen, Q; Feng, CB; Guo, ZH; Hu, ZQ; Liu, F; Liu, Y; Miao, Y; Qu, Q; Shi, PL, 2019) |
| "Androgenetic alopecia is the most common type of hair loss in men, which is manifested by a progressive terminal hair loss in specific areas of scalp." | ( Banihashemi, M; Bayat, M; Hamidi Alamdari, D; Salehi, M; Yazdanpanah, MJ, 2019) |
| "Additionally, hair loss is known to occur during menopause in women owing to decreased estrogen secretion." | ( Horie, K; Nanashima, N, 2019) |
| "Androgenic alopecia is a common and unpleasant problem that directly influences the self-confidence and individual life quality." | ( Asnaashari, S; Javadzadeh, Y, 2020) |
| "Hair loss is a common dermatosis symptom and side-effect in cancer chemotherapeutics." | ( Chen, K; Qi, S; Wang, B; Wang, L; Wang, W; Yang, J, 2020) |
| "Androgenetic alopecia is a stressful condition for males." | ( Alarawi, A; Bessar, H; Ghonemy, S, 2021) |
| "Androgenetic alopecia is a common form of scalp hair loss that affects men in their mid-twenties and increases with age." | ( Eum, J; Jung, H; Kim, S; Yang, H, 2019) |
| "Pattern hair loss is a very common skin disorder, but more therapeutic modalities for hair growth are still required." | ( Jang, YH; Kim, JY; Lee, SJ; Lee, WJ; Park, KD; Sohng, C, 2020) |
| "Hair loss is one of the most common side effects of chemotherapy, and can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life." | ( Cao, YL; Chen, JP; Guo, L; Guo, Z; Huang, M; Lin, MD; Liu, HL; Qu, WL; Shi, XL; Sun, YZ; Xu, Q; You, JS, 2019) |
| "Hair loss is known to negatively affect the quality of life and predispose to depression and anxiety." | ( Becker, M; Klenk, A; Koch, N; Völker, JM, 2020) |
| "Hair loss is a common problem in dermatological patients." | ( Adamski, Z; Dańczak-Pazdrowska, A; Mikiel, D; Polańska, A; Żaba, R, 2021) |
| "Treatment for hair loss is largely limited, and any beneficial effects are often transient." | ( Chang, M; Ha, JC; Han, K; Jung, N; Kim, CH; Kim, N; Kim, YJ; Lee, J; Park, JH, 2020) |
| "Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined." | ( Cesetti, MV; Chartuni, JCN; Costa, IMC; Gavioli, CFB; Lemes, AM; Takano, GHS; Uzel, BPC, 2021) |
| "Androgenic alopecia is a genetically determined and leads to a progressive hair loss of the vertex, affecting both men and women." | ( Castronovo, C; Kaux, JF; Moreau, T; Nikkels, AF; Paquet, P, 2021) |
| "Pattern hair loss is the most common type of hair loss in both men and women." | ( Bergfeld, WF; Tamashunas, NL, 2021) |
| "Hair loss is a common complication after metabolic and bariatric surgery (MBS)." | ( Chen, W; Fan, M; Mahawar, K; Parmar, C; Wang, C; Yang, W; Zhang, W, 2021) |
| "Hair loss is common after MBS especially in younger women, and those with low serum levels of zinc, folic acid, and ferritin." | ( Chen, W; Fan, M; Mahawar, K; Parmar, C; Wang, C; Yang, W; Zhang, W, 2021) |
| "Men with early-onset androgenetic alopecia are characterized by hormonal profiles similar to those observed in women with polycystic ovary syndrome." | ( Basiak, M; Krysiak, R; Okopień, B, 2021) |
| "Whereas hair loss is frequently associated with mood stabilizers, rarely ,it is also attributed to antidepressants." | ( Kamış, GZ; Kurhan, F, 2021) |
| "Early-onset male-pattern baldness is considered the phenotypic equivalent of polycystic ovary syndrome in men." | ( Basiak, M; Krysiak, R; Okopień, B, 2021) |
| "Hair loss is a frequent adverse effect that may occur by psychotropic drug use and that can remit by its cessation." | ( Akyüz Karacan, F; Kırpınar, I; Tangılntız, A, 2021) |
| "Male-pattern baldness is accompanied by mildly increased androgen levels." | ( Kowalcze, K; Krysiak, R; Marek, B; Okopień, B, 2021) |
| "Early-onset androgenic alopecia is considered the phenotypic equivalent of polycystic ovary syndrome in men." | ( Kowalcze, K; Krysiak, R; Okopień, B, 2022) |
| "Androgenic alopecia is a common type of hair loss, usually caused by testosterone metabolism generating dihydrotestosterone and hair follicular micro-inflammation." | ( Chakkavittumrong, P; Chantakul, R; Ingkaninan, K; Neungchamnong, N; Waranuch, N; Wisuitiprot, V; Wisuitiprot, W, 2022) |
| "Androgenetic alopecia is defined as a patterned hair loss resulting from the effect of androgen on hair follicles and characterized by non-scarring, progressive miniaturization of the hair follicles." | ( Faghihi, G; Hoseyni, MS; Iraji, F; Jelvan, M; Saber, M; Siadat, AH, 2022) |
| "Although hair loss is usually reversible, regrowth can take months, causing greater psychological distress." | ( Amarillo, D; Cuello, M; de Boni, D, 2022) |
| "Alopecia or hair loss is a widespread issue that has significant effects on personal well-being for both genders nationally and internationally." | ( Al-Mahdy, DA; Choucry, MA; El-Askary, H; Sayed, RH; Youssef, A, 2022) |
| "Male androgenetic alopecia is a common condition and represents a major concern for patients who experience this condition." | ( Domínguez-Santas, M; Grimalt, R; Saceda-Corralo, D; Vañó-Galván, S, 2023) |
| "HIGHLIGHTS: • Androgenic alopecia is a polygenetic disorder with gradual loss of hair that progresses with age." | ( Ahmed, N; Saleem, K; Siddiqui, B; Taqi, MM; Ur Rehman, A, 2022) |
| "Hair loss is caused by various factors." | ( Cho, E; Jang, Y; Jung, E; Park, D; Roh, KB; Ryu, D; Woo, J; You, J, 2023) |
| "Hair loss is caused by various factors." | ( Cho, E; Jang, Y; Jung, E; Park, D; Roh, KB; Ryu, D; Woo, J; You, J, 2023) |
| "Hair loss is caused by various factors." | ( Cho, E; Jang, Y; Jung, E; Park, D; Roh, KB; Ryu, D; Woo, J; You, J, 2023) |
| "Pediatric androgenetic alopecia is an underrecognized disorder." | ( Gomes, TF; Soares, RO, 2023) |
| "While hair loss is not life-threatening, it can cause significant anxiety, depression, and other psychological problems, ultimately impacting an individual's quality of life." | ( Beley, N; Bjørklund, G; Fedorovska, M; Gasmi, A; Komisarenko, A; Lenchyk, L; Lysiuk, R; Muhammad, A; Mujawdiya, PK; Noor, S; Piscopo, S; Shanaida, M; Strus, O, 2023) |
| "Pattern-type hair loss is a highly prevalent condition affecting the majority of men and women at some point in their lifetime." | ( Abidi, Z; Arruda, S; Rapaport, J; Sadgrove, NJ; Sadick, N; Swearingen, A, 2023) |
| "Patterned hair loss is a common type of non-scarring alopecia, characterized by miniaturization of hair follicles." | ( Deoghare, S; Sadick, NS, 2023) |
| "Androgenetic alopecia is a widespread condition that is the most common type of hair loss affecting approximately 58% and 40% of men and women by the age of 50, respectively." | ( Abdi, P; Anthony, MR; Awad, C; Farkouh, C; Kenny, B; Maibach, HI; Ogunyemi, B, 2023) |
| Excerpt | Reference |
|---|
| "The antiandrogenic treatment of androgenetic alopecia, hirsutism and androgenetic acne--with their underlying hormonal disturbance, consisting in an increased production of androgens, represents an quasi etiological therapy." | ( Ludwig, E; Zaun, H, 1978) |
| "Women suffering from severe acne, androgenic alopecia, or idiopathic hirsutism should be treated with higher doses of antiandrogens." | ( Braendle, W; Leidenberger, F, 1976) |
| "As for side effects, hair loss and gastrointestinal disorders were frequently documented low grade and less following administration of epi-ADM as compared to ADM." | ( Aikawa, T; Furukawa, J; Kaji, M; Kobayashi, T; Kotsuma, Y; Maeura, Y; Takatsuka, Y; Yayoi, E, 1992) |
| "One patient had no hair loss in either the treatment or control area." | ( Baden, H; Frederickson, H; Gajewski, W; Goldstein, A; Goodman, A; Granai, CO, 1991) |
| "10 male test persons with androgenetic alopecia (Hamilton stage IV) were topically treated with an alcoholic 17 alpha-propylmesterolone solution (PM, 3%) for 3 months." | ( Kiesewetter, F; Schell, H; Seidel, C; von Hintzenstern, J, 1990) |
| "Thirty-one men with androgenetic alopecia completed 4 1/2 to 5 years of therapy with 2% and 3% topical minoxidil." | ( Amara, IA; DeLong, ER; Olsen, EA; Weiner, MS, 1990) |
| "Alopecia (hair loss) is among the most distressing side effects of cancer chemotherapy." | ( Hussein, AM; Jimenez, JJ; McCall, CA; Yunis, AA, 1990) |
| "Ten male patients suffering from androgenetic alopecia were treated during one year with a lotion containing 1% 11a-hydroxyprogesterone." | ( Peereboom-Wynia, JD; Stolz, E; van der Willigen, AH; van Joost, T, 1987) |
| "Twenty female patients suffering from androgenetic alopecia were treated during one year with 50 micrograms ethinyloestradiol plus 2 mg cyproterone acetate and additional 20 mg cyproterone acetate on days 5-20 of the menstrual cycle." | ( Peereboom-Wynia, JD; Stolz, E; van der Willigen, AH; van Joost, T, 1989) |
| "Forty-seven men with male pattern baldness were treated in a double-blind clinical trial with topical 2% minoxidil or placebo." | ( Cotterill, PC; James, KC; Kingsley, P; Rushton, DH; Unger, WP, 1989) |
| "Ten men with male pattern baldness who had been treated with 2% or 3% minoxidil for at least 4 months were evaluated for any changes in scalp hair growth on and off drug." | ( Olsen, EA; Weiner, MS, 1987) |
| "Ten white women with moderate to severe androgenetic alopecia were treated with cimetidine 300 mg by mouth five times a day." | ( Aram, H, 1987) |
| "Alopecia (hair loss) is often singled out as the most distressing side-effect of cancer chemotherapy treatment." | ( Tierney, AJ, 1987) |
| "Frontotemporal hair loss did not respond to treatment and in fact progressed in severity, despite the twice-daily applications of minoxidil." | ( DeVillez, RL, 1987) |
| "Four patients developed hair loss, depigmentation of hair, ichthyosis, and blepharoconjunctivitis during treatment with large doses of dixyrazine (Esucos, UCB, Belgium)." | ( Poulsen, J, 1981) |
| "Two cases of hair loss attributed to lithium therapy are presented." | ( Ananth, J; Yassa, R, 1983) |
| "Ten of the 11 patients (91%) had severe hair loss by the end of the second course of chemotherapy." | ( Goplerud, DR; Krebs, HB; Myers, MB; Wheelock, JB, 1984) |
| "A strategy of surgical treatment for male pattern baldness has been conceived using a combination of flaps and tissue expansion." | ( Trott, JA, 1993) |
| "Five women affected by androgenetic alopecia developed severe hypertrichosis of the face and limbs after 2-3 months of treatment with 5% topical minoxidil." | ( Misciali, C; Peluso, AM; Tosti, A; Vincenzi, C, 1997) |
| "Atopic patients who experience seasonal hair loss may benefit (ie, have less severe hair loss flares or respond more readily to topical therapy) by using an antihistamine or mast cell stabilizer prophylactically." | ( Alaiti, S; Fiedler, VC, 1996) |
| "Protection from hair loss was achieved by maintaining scalp temperatures below 15 degrees C before, during and after chemotherapy by frequent changing of the caps." | ( Bamias, A; Katsimbri, P; Pavlidis, N, 2000) |
| "We describe massive hair loss in a 51-year-old woman during treatment with Seroxat (paroxetine), which remitted after it was discontinued." | ( Dorevitch, A; Sella, A; Umansky, L, 2000) |
| "In previous clinical trials in men with androgenetic alopecia, treatment with finasteride increased scalp hair counts in a defined area (i." | ( Calvieri, S; Fuh, V; Guarrera, M; He, W; Kanojia, P; Kaufman, KD; Kopera, D; Lopez-Bran, E; Prens, E; Roberts, J; Sanchez-Pedreno, P; Stene, JJ; Tosti, A; Van Neste, D; Whiting, D; Wolff, H, 2000) |
| "Alopecia (hair loss) symptoms were also significantly improved with topical treatment with M50054." | ( Hosaka, Y; Kato, K; Mochizuki, H; Muramatsu, H; Nagata, S; Nakamura, N; Nakayama, K; Ohmori, Y; Saitoh, F; Takiguchi, K; Tsuda, T, 2001) |
| "For topical treatment of androgenetic alopecia (AGA) in women, solutions containing either estradiol benzoate, estradiol valerate, 17beta- or 17alpha-estradiol are commercially available in Europe and some studies show an increased anagen and decreased telogen rate after treatment as compared with placebo." | ( Happle, R; Hoffmann, R; Huth, A; Kissling, S; Niiyama, S, 2002) |
| "However, DFMO treatment led to marked hair loss in PKC epsilon transgenic mice." | ( Ness, KJ; Oberley, TD; Verma, AK; Wheeler, DL, 2003) |
| "Most patients were men treated for androgenic alopecia." | ( Kolasiñski, J; Kolenda, M, 2003) |
| "Minoxidil has been widely used to treat androgenetic alopecia, but little is known about its pharmacological activity or about the identity of its target cells in hair follicles." | ( Cho, KH; Chung, JH; Eun, HC; Han, JH; Kim, KH; Kwon, OS, 2004) |
| "Pharmacologic management of pattern hair loss is an active area of research, and clinicians should be aware of new data and treatment modalities." | ( Haber, RS, 2004) |
| "A total of 186 patients with androgenetic alopecia were evaluated before and 4 to 6 months after the initiation of finasteride therapy (1 mg)." | ( Atzori, L; Barbareschi, M; Benci, M; Pazzaglia, M; Rebora, A; Rossi, A; Soli, M; Tosti, A; Vena, GA; Voudouris, S, 2004) |
| "The remarkable scalp hair loss started within a week after CBZ administration." | ( Ishii, A; Kohno, Y; Shoji, S, 2004) |
| "Chemotherapy-induced temporary hair loss is one of the most common and distressing side-effects of cancer therapy." | ( Breed, WP; Grevelman, EG, 2005) |
| "To investigate the process of cytotoxic hair loss and any protective effect on the hair of pretreatment with topical calcipotriol." | ( Bleiker, TO; Hutchinson, PE; Nicolaou, N; Traulsen, J, 2005) |
| "For men with androgenetic alopecia, therapy with finasteride 1 mg daily from 4 weeks before until 48 weeks after hair transplant improves scalp hair surrounding the hair transplant and increases hair density." | ( Barusco, M; Kaufman, KD; Leavitt, M; Perez-Meza, D; Rao, NA; Ziering, C, 2005) |
| "Thirty-seven women with female pattern hair loss were treated with oral finasteride, 2." | ( Iorizzo, M; Piraccini, BM; Tosti, A; Vincenzi, C; Voudouris, S, 2006) |
| "The scheme of hair loss treatment, by means of preparations affecting pathogenetical mechanisms of diffuse hair loss development is offered." | ( Tsiskarishvili, NV; Tsiskarishvili, TsI, 2007) |
| "Commonly occurring hair loss in children in our region is mainly acquired, and the clinical course is related to the parent's attitude to treatment, particularly for tinea capitis." | ( Maduechesi, C; Nnoruka, EN; Obiagboso, I, 2007) |
| "Chemotherapy-induced hair loss is perceived as burdensome." | ( Breed, WP; Mols, F; van den Hurk, CJ; Vingerhoets, AJ, 2009) |
| "There was no report of hair loss during the fluoxetine therapy." | ( Ghanizadeh, A, 2008) |
| "Male and female pattern hair loss affects a large percentage of the population, and patients frequently present for treatment of this to their dermatologist." | ( Avram, MR; Rogers, NE, 2008) |
| "Finasteride, used for treatment of androgenetic alopecia at a dose of 1mg/day, is an effective inhibitor of type II 5alpha-reductase, the enzyme responsible for the reduction of testosterone to dihydrotestosterone." | ( Duskova, M; Hill, M; Starka, L, 2010) |
| "While androgenetic alopecia (AGA) is the most common form of hair loss in adults, little is known about its prevalence, clinical features and response to treatments in the paediatric population." | ( Cantatore-Francis, J; Gonzalez, ME; Orlow, SJ, 2010) |
| "Traditional methods of treating hair loss have included minoxidil, finasteride, and surgical transplantation." | ( Ghanaat, M, 2010) |
| "Fortunately, chemotherapy-induced hair loss is mostly reversible, and appropriate hair and scalp care and temporarily wearing a wig may be the most effective coping strategy." | ( Trüeb, RM, 2010) |
| "A total of 113 women with androgenetic alopecia were randomized to 24 weeks of treatment with 5% MTF or 2% MTS." | ( Blume-Peytavi, U; Canfield, D; Dietz, E; Garcia Bartels, N; Hillmann, K, 2011) |
| "The fact that no subject complained of hair loss as a result of treatment casts doubt on the presumed role of testosterone in driving female scalp hair loss." | ( Dimitrakakis, C; Glaser, RL; Messenger, AG, 2012) |
| "Increased hair loss which can occur during Minoxidil use, is due to the synchronization of the hair cycle that the treatment induces." | ( Calvieri, S; Cantisani, C; Iorio, A; Melis, L; Rossi, A; Scali, E, 2012) |
| "Treatment of female pattern hair loss (FPHL) is frustrating for both patients and doctors." | ( Abd-Elaziz, G; Ahmed, N; Ghannam, B; Hamed, Y; Ibrahim, M; Moftah, N, 2013) |
| "Chemotherapy-induced hair loss is one of the most serious and feared adverse effects of cancer therapy." | ( D'Agostini, F; De Flora, S; Fiallo, P; Ghio, M, 2013) |
| "Because androgenetic alopecia is progressive in nature, stabilization of the process using medical therapy is an important adjunct to any surgical hair-restoration plan." | ( Nusbaum, AG; Nusbaum, BP; Rose, PT, 2013) |
| "Chemotherapy-induced hair loss (alopecia) (CIA) is one of the most feared side effects of chemotherapy among cancer patients." | ( Chu, J; Deslongchamps, P; Dow, LE; Lowe, SW; Nasr, Z; Paquet, M; Pelletier, J; Porco, JA; Ravindar, K; Somaiah, R, 2013) |
| "The onset, pattern and amount of hair loss differ depending on the therapy regimen and have not yet been quantified using standardized techniques." | ( Bangemann, N; Blume-Peytavi, U; Garcia Bartels, N; Hillmann, K; Kanti, V; Kleine-Tebbe, A; Lindner, J; Nuwayhid, R; Stroux, A, 2014) |
| "Diffuse hair loss begins shortly after initiation of chemotherapy, mainly as anagen effluvium, with a proportion of anagen to telogen conversion." | ( Bangemann, N; Blume-Peytavi, U; Garcia Bartels, N; Hillmann, K; Kanti, V; Kleine-Tebbe, A; Lindner, J; Nuwayhid, R; Stroux, A, 2014) |
| "Having noted increasing hair loss among our patients treated with voriconazole, we sought to determine the prevalence and characteristics of alopecia associated with this agent." | ( Kauffman, CA; Kerr, L; Malani, AN; Obear, J; Singal, B, 2014) |
| "The authors followed Japanese men with androgenetic alopecia treated with finasteride for 5 years to evaluate long-term treatment efficacy." | ( Akimoto, M; Inoue, Y; Nemoto, M; Ohki, K; Otsuka, S; Sato, A; Shimakura, Y; Takeda, A; Yamawaki, T; Yoshitake, T, 2015) |
| "To review treatment options for hair loss in women." | ( Check, JH; Cohen, R, 2015) |
| "Adenosine is an effective treatment for androgenetic alopecia (AGA) in Japanese men and women." | ( Ehama, R; Ideta, R; Iino, M; Iwabuchi, T; Kishimoto, J; Kobayashi, T; Nakazawa, Y; Ohyama, M; Yamanishi, H, 2016) |
| "Appreciation of different types of hair loss (alopecia) that may be encountered in hospital medicine is important to ensure accurate diagnosis and management, identify underlying medical conditions or treatments that may present with increased hair loss, recognise autoimmune alopecias and their associations, and understand the significant psychological impact of hair loss on an individual." | ( Harries, M; Nalluri, R, 2016) |
| "Current androgenetic alopecia treatments are limited to hair transplantation and medications that inhibit dihydrotestosterone, a potent androgen associated with follicular micronization." | ( Ganzer, CA; Jacobs, AR, 2018) |
| "Chemotherapy-induced hair loss is one of the most devastating side effects of cancer treatment." | ( Botchkarev, VA; Sharov, AA, 2016) |
| "Chemotherapy-induced hair loss is a common and distressing side effect." | ( Andrews, K; Baylock, B; Boyle, F; O'Reilly, A; Pugliano, L; Shaw, J; Winstanley, J, 2016) |
| "Transient hair loss is not a reported side effect of dimethyl-fumarate therapy but by excluding any known cause we attributed it to the beginning of the new therapy." | ( De Fino, C; Losavio, FA; Lucchini, M; Mirabella, M; Nociti, V, 2016) |
| "Some men who use finasteride for hair loss report persistent sexual and other symptoms after discontinuing finasteride therapy." | ( Amr, S; Basaria, S; Bhasin, S; Bhawan, J; Dury, AY; Gonthier, R; Huang, G; Jasuja, R; Labrie, F; Li, Z; O'Leary, M; Pan, H; Papazian, A; Pencina, K; Serra, C; Stern, E; Storer, TW; Travison, TG; Wharton, W, 2016) |
| "Self-estimated hair loss using the Dean scale was assessed 4 weeks after the last dose of chemotherapy by unblinded patient review of 5 photographs." | ( Bågeman, E; Cigler, T; D'Agostino, RB; Esserman, L; Hurvitz, SA; Klein, P; Melin, SA; Melisko, ME; Mitchel, J; Moore, A; Park, G; Rugo, HS; Ver Hoeve, ES, 2017) |
| "Genotoxicity-induced hair loss from chemotherapy and radiotherapy is often encountered in cancer treatment, and there is a lack of effective treatment." | ( Chan, CC; Chang, M; Chen, YT; Chi, P; Chiu, HY; Huang, WY; Lai, SF; Lee, HS; Lin, SJ; Plikus, MV; Tsao, PN; Yang, TL, 2017) |
| "Female pattern hair loss (FPHL) presents with diffuse thinning over the mid-frontal scalp, for which various treatment modalities have been tried." | ( Lew, BL; Sim, WY; Won, YY, 2018) |
| "Considering that no current hair loss-related products can completely reverse hair loss, it is reasonable to believe this market could expand significantly with the discovery of a comprehensive therapy." | ( Higgins, CA; Pantelireis, N, 2018) |
| "Forty men aged 18-60 years with androgenetic alopecia were randomized to 24 weeks of treatment with a finasteride/minoxidil or minoxidil solution twice daily." | ( Chalermroj, N; Khunkhet, S; Srisuwanwattana, P; Suchonwanit, P, 2018) |
| "Patients reported degree of hair loss using the Dean score on day 1 of each cycle and following the last chemotherapy." | ( Bauwens, A; Chan, A; Chih, J; Ernenwein, T; Jackson, S; McGlone, F; Pontre, S; Reid, C, 2018) |
| "Severe hair loss related to PD treatment was reported in 43 cases (0." | ( Bleich, S; Burda, K; Druschky, K; Frieling, H; Grohmann, R; Hillemacher, T; Neyazi, A; Stübner, S; Toto, S, 2018) |
| "Treatment of male androgenetic alopecia with 5α-reductase inhibitors is efficacious." | ( Choe, SJ; Lee, S; Lee, WS; Lee, YB, 2019) |
| "Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors." | ( Coskuner, ER; Culha, MG; Ozkan, B, 2019) |
| "The most infallible approach to male pattern baldness (MPB) is hair transplantation in the thinning area in parallel to medical treatment to prevent further alopecia progression." | ( Kim, N; Park, JH; You, SH, 2019) |
| "Meanwhile, other forms of hair loss were studied such as alopecia, lichen planopilaris, and frontal fibrosing alopecia, but no RCTs evaluating finasteride therapy were identified." | ( Chapman, LW; Hu, AC; Mesinkovska, NA, 2019) |
| "The mean time from chemotherapy until hair loss was 18." | ( Hasegawa, Y; Imai, H; Nozawa, K; Ohashi, Y; Okada, H; Saito, M; Sangai, T; Shimozuma, K; Takayama, T; Tamai, N; Watanabe, T; Yagata, H; Yajima, T; Yamaguchi, T; Yoshida, Y; Yoshimura, A, 2019) |
| "Failure to prevent hair loss in patients undergoing an expensive and potentially uncomfortable treatment likely contributes to decreased well-being, impacting the overall distribution of QoL measures in scalp cooling patients compared to controls." | ( Hagigeorges, D; Isakoff, SJ; Lacouture, ME; Manatis-Lornell, AJ; Marks, DH; Okhovat, JP; Senna, MM, 2019) |
| "The treatment of hair loss is a challenge for all dermatologists." | ( Santos, LDN; Shapiro, J, 2019) |
| "Ebastine has also shown to affect hair loss; however, the immunoregulatory effect of ebastine cannot completely exclude the possibility of spontaneous hair regrowth in ebastine-treated mice." | ( Chen, ML; Lee, MC; Li, CH; Lin, YY; Tsai, FM; Wang, CH; Wang, LK, 2019) |
| "In early male hair loss, this therapy demonstrated a statistically significant increase in terminal hair counts relative to the control population at 24 weeks and represents a promising approach for early androgenetic alopecia." | ( Aronowitz, J; Brown, W; Daniels, EJ; Epstein, J; Geronemus, RG; Glasgold, MJ; Kuka, G; Rogal, JG; Washenik, K, 2020) |
| "In early male hair loss, this therapy demonstrated a statistically significant increase in terminal hair counts relative to the control population at 24 weeks and represents a promising approach for early androgenetic alopecia." | ( Aronowitz, J; Brown, W; Daniels, EJ; Epstein, J; Geronemus, RG; Glasgold, MJ; Kuka, G; Rogal, JG; Washenik, K, 2020) |
| "Various treatments exist for androgenetic alopecia (AGA); we determined the relative efficacies of non-surgical AGA monotherapies separately for men and women." | ( Bamimore, MA; Foley, KA; Gupta, AK, 2022) |
| "Early diagnosis and treatment of hair loss disorders is vital in providing patients with improved psychological outcomes." | ( Asghari, A; Choi, F; Csuka, E; Ekelem, C; Feil, N; Heydarlou, D; Juhasz, M; Lin, J; Mesinkovska, NA, 2021) |
| "Treatment of androgenetic alopecia (AGA) with concurrent electrodynamic microneedling and 5% minoxidil may further stimulate hair growth." | ( Bao, L; Fang, S; Li, Y; Zheng, L; Zong, H, 2022) |
| "He was on treatment for androgenic alopecia with topical 5% Minoxidil application on scalp two times a day." | ( Jain, K; Pereira, A; Venkatesh, R; Yadav, NK, 2020) |
| "Chemotherapy-induced hair loss (alopecia) (CIA) remains a major unsolved problem in clinical oncology." | ( Ao, X; Farjo, B; Farjo, N; Haslam, IS; Huang, Z; Paus, R; Rutkowski, D; Smart, E; Teng, X; Wierzbicka, J; Xie, G; Yan, Z; Yue, Z; Zhang, Y; Zhou, G; Zhou, Y, 2021) |
| "In spite of several modalities for androgenic alopecia therapy used such as topical minoxidil solution or oral finasteride; it still has a great challenge." | ( Makki, M; Salah, I; Younes, AH, 2020) |
| "Alopecia areata (AA) is an autoimmune hair loss condition that is difficult to treat and frequently disruptive to the psychosocial well-being of patients." | ( Chen, Z; Choi, F; Csuka, E; Ekelem, C; Heidari, AE; Hosking, AM; Juhasz, M; Mesinkovska, NA; Pham, CT; Rapaport, JA; Valdebran, M; Yu, J, 2020) |
| "Treatment for hair loss is largely limited, and any beneficial effects are often transient." | ( Chang, M; Ha, JC; Han, K; Jung, N; Kim, CH; Kim, N; Kim, YJ; Lee, J; Park, JH, 2020) |
| "Female androgenetic alopecia is one cause of alopecia in women, although the ideal treatment for this condition remains far from defined." | ( Cesetti, MV; Chartuni, JCN; Costa, IMC; Gavioli, CFB; Lemes, AM; Takano, GHS; Uzel, BPC, 2021) |
| "In a small cohort of androgenetic alopecia men, adding the SULT1A1 adjuvant to their daily minoxidil treatment regimen improved hair regrowth." | ( Daruwalla, S; Dhurat, R; Goren, A; Kovacevic, M; McCoy, J; Pai, S; Shapiro, J; Sinclair, R; Vano-Galvan, S, 2022) |
| "The current medical treatments of androgenetic alopecia (AGA) have hardly achieved a satisfying clinical improvement." | ( Bongiorno, MR; Mazzola, G; Patti, I; Pistone, G; Sorce, M, 2021) |
| "It should be kept in mind that hair loss may be observed in patients treated with fluoxetine and should be questioned in both male and female." | ( Akyüz Karacan, F; Kırpınar, I; Tangılntız, A, 2021) |
| "Six patients had progression of their hair loss in spite of treatment." | ( Bhoyrul, B; Jerjen, R; Pinczewski, J; Sinclair, R, 2021) |
| "To highlight treatment options for androgenetic alopecia taking into consideration the efficacy, side effect profiles, practicality of treatment (compliance), and costs to help clinicians offer ethically appropriate treatment regimens to their patients." | ( Ablon, G; Fischer, DL; Gade, A; Han, H; Nestor, MS, 2021) |
| "Alopecia or hair loss in children is an important and often challenging problem to diagnose and treat." | ( Gold, M; Goldust, M; Grabbe, S; Mishra, P; Patil, A; Rudnicka, L; Sinclair, R, 2022) |
| "Chemotherapy-induced hair loss in cancer is usually temporary but can take a significant emotional toll on patients and lead to treatment refusal in many cases." | ( Amarillo, D; Cuello, M; de Boni, D, 2022) |
| "Thirty-seven patients with androgenic alopecia were treated with finasteride and minoxidil as standard therapy and were randomly assigned to subcutaneous injections of botulinum toxin A in one hemisphere of the head at the beginning of a 6-month treatment." | ( Gao, S; Jia, Z; Li, K; Tian, K; Wu, L; Xu, W, 2022) |
| "The development of painless hair loss therapy without side-effect is challenging." | ( Chen, X; Kong, M; Li, H; Qin, D; Qiu, K; Shi, Y; Yu, M; Zhang, W; Zhao, J, 2022) |
| "Men and woman are affected by hair loss, but the pathophysiology of the hair loss is thought to be different between sexes; therefore, gender must play a role in treatment decisions." | ( Sand, J; Walen, S, 2022) |
| "A 16-year-old woman with MG developed hair loss, pancytopenia, bloody diarrhea, and fever shortly after azathioprine treatment." | ( Hsu, WY; Lin, LC; Lin, PC; Liu, YC, 2022) |
| "The main outcome measure was alopecia (hair loss>50%) during and after chemotherapy treatment." | ( Abt-Sack, A; de Armas-Castellano, A; Del Pino-Sedeño, T; González-Hernández, Y; González-Pacheco, H; Infante-Ventura, D; Ramallo-Fariña, Y; Rueda Domínguez, A; Serrano-Aguilar, P; Trujillo-Martín, MM, 2023) |
| "Men and woman are affected by hair loss, but the pathophysiology of the hair loss is thought to be different between sexes; therefore, gender must play a role in treatment decisions." | ( Sand, J; Walen, S, 2023) |
| "The psychological distress caused by hair loss may cause patients to discontinue chemotherapy, affecting the efficacy of the treatment." | ( Guan, Y; Liu, M; Ma, K; Qiang, W; Ruan, R; Sun, H; Yan, A; Yang, C; Zhu, H, 2023) |
| "CDKiA was clinically similar to androgenetic alopecia and specific vertex involvement was more common in patients treated with CDK4/6i + ET than endocrine monotherapy (n = 7 [70." | ( Cathcart-Rake, E; Cherian, M; Dulmage, B; Gatti-Mays, M; Loprinzi, CL; Lustberg, M; Minta, A; Park, C; Ramaswamy, B; Rose, L; Ruddy, KJ; Sardesai, S; Stover, D; Sudheendra, P; Trovato, S; Wesolowski, R; Williams, N, 2023) |